Difference between revisions of "Streptozocin (Zanosar)"
m |
m (→References) |
||
| Line 24: | Line 24: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| + | |||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:Nitrosureas]] | [[Category:Nitrosureas]] | ||
Revision as of 21:48, 25 November 2014
Also known as STZ.
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.[1][2][3]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Streptozocin (Zanosar) patient drug information from manufacturer[4]
- Streptozocin (Zanosar) patient drug information (Chemocare)[5]
- Streptozocin (Zanosar) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 5/7/1982: Initial FDA approval
References
- ↑ 1.0 1.1 Streptozocin (Zanosar) package insert
- ↑ Streptozocin (Zanosar) package insert (locally hosted backup)
- ↑ Zanosar manufacturer's website
- ↑ Streptozocin (Zanosar) patient information from manufacturer
- ↑ Streptozocin (Zanosar) patient drug information (Chemocare)
- ↑ Streptozocin (Zanosar) patient drug information (UpToDate)